Corpus Intelligence IC Memo — BAYSTATE FRANKLIN MEDICAL CENTER 2026-04-26 10:37 UTC
IC Memo — BAYSTATE FRANKLIN MEDICAL CENTER
Investment Committee Memorandum | MA | 89 beds | Grade C | EBITDA uplift $7.2M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

BAYSTATE FRANKLIN MEDICAL CENTER

CCN 220016 | FRANKLIN, MA | 89 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

BAYSTATE FRANKLIN MEDICAL CENTER is a 89-bed under-performing / distressed in FRANKLIN, MA with $98.1M in net patient revenue and a -23.1% operating margin. The hospital serves a payer mix of 34.9% Medicare, 11.9% Medicaid, and 53.3% commercial.

Thesis: Turnaround. Our ML models identify $7.2M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -23.1% to -15.7% (+736bps).

Net Revenue HCRIS$98.1M
Current EBITDA COMPUTED$-22.7M
Operating Margin COMPUTED-23.1%
Occupancy HCRIS60.1%
Revenue / Bed COMPUTED$1.1M
Net-to-Gross HCRIS33.2%
Distress Probability ML48.5%

2. Market Context & Competitive Position

99
MA Hospitals
-12.2%
State Median Margin
50
Comparable Hospitals

MA has 99 Medicare-certified hospitals with a median operating margin of -12.2%. The target's margin of -23.1% places it below the state median. Among 50 size-comparable peers (44-178 beds), the median margin is -7.9%. The target's below-peer margin suggests operational improvement opportunity.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (44-178), prioritizing same-state peers. 50 hospitals in the comp set.

HospitalStateBedsRevenueMargin
BAYSTATE FRANKLIN MEDICAL CENT (Target)MA89$98.1M-23.1%
BETH ISRAEL DEACONESS - PLYMOUMA150$349.1M2.6%
STEWARD ST. ANNES HOSPITALMA175$322.3M12.8%
FAULKNER HOSPITALMA147$316.6M-7.9%
EMERSON HOSPITALMA111$315.1M-10.1%
WINCHESTER HOSPITALMA178$314.9M-3.9%
BROCKTON HOSPITAL INC.MA175$305.2M-18.4%
THE MERCY HOSPITALMA150$276.4M-12.5%
MILFORD REGIONAL MEDICAL CENTEMA148$254.6M-7.2%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $7.2M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$2.1M+210bp18mo
Cost to Collect4.5%2.5%$2.0M+200bp12mo
Denial Rate Reduction12.0%6.5%$1.9M+198bp12mo
A/R Days Reduction5200.0%3800.0%$1.2M+122bp9mo
Clean Claim Rate88.0%96.0%$63K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$2.1M
Cost to Collect
$2.0M
Denial Rate Reduction
$1.9M
A/R Days Reduction
$1.2M
Clean Claim Rate
$63K
Total EBITDA Uplift$7.2M
Current EBITDA$-22.7M
+ RCM Uplift+$7.2M
Pro Forma EBITDA$-15.4M
Current Margin-23.1%
Pro Forma Margin-15.7%
WC Released (1x)$3.8M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-34.9M$-77.3M0.00x-100.0%
Base (11x exit)10.0x11.0x$-34.9M$-96.3M0.00x-100.0%
Bull Case9.0x11.0x$-31.4M$-83.8M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-31.4M$-100.7M0.00x-100.0%
Bear Case11.0x10.0x$-38.3M$-102.1M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-38.3M$-124.7M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 50 hospitals with 44-178 beds
  • Same-state prioritization (n=51)
  • Comp margins: P25=-16.9% / P50=-7.9% / P75=2.2%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.